![Alex White](https://profiles-cardiff.imgix.net/attachments/2971?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
Major interests concern the design and synthesis of novel anti-cancer agents. This involves synthetic organic chemistry, molecular modelling, purification methods and spectroscopy, particularly high field NMR, and close collaboration with biochemists. Particularly of interest is the development of natural product lead compounds as clinically useful chemotherapeutic agents.
Cyhoeddiad
2019
- Owen, L., White, A. W. and Laird, K. 2019. Characterisation and screening of antimicrobial essential oil components against clinically important antibiotic-resistant bacteria using thin layer chromatography-direct bioautography hyphenated with GC-MS, LC-MS and NMR. Phytochemical Analysis 30(2), pp. 121-131. (10.1002/pca.2797)
2013
- Lau, W. M., Heard, C. M. and White, A. W. 2013. Design, synthesis and in vitro degradation of a novel co-drug for the treatment of psoriasis. Pharmaceutics 5(2), pp. 232-245. (10.3390/pharmaceutics5020232)
2012
- White, A. W., Carpenter, N., Lottin, J. R. P., McClelland, R. and Nicholson, R. 2012. Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. European Journal of Medicinal Chemistry 56, pp. 246-253. (10.1016/j.ejmech.2012.08.022)
2011
- Lau, W. M., Ng, K. W., White, A. W. and Heard, C. M. 2011. Therapeutic and cytotoxic effects of the novel antipsoriasis codrug, naproxyl-dithranol, on HaCaT cells. Molecular Pharmaceutics 8(6), pp. 2398-2407. (10.1021/mp200327k)
2010
- Lau, W. M., White, A. W., Donaldson, M. and Heard, C. M. 2010. Histochemical visualisation of esterase activity in porcine ear skin. Journal of Pharmacy and Pharmacology 62(6), pp. 798-798. (10.1211/jpp.62.06.0016)
- Lau, W. M., White, A. W. and Heard, C. M. 2010. Topical delivery of a naproxen-dithranol co-drug: in vitro skin penetration, permeation, and staining. Pharmaceutical Research 27(12), pp. 2734-2742. (10.1007/s11095-010-0274-8)
2008
- Lau, W. M., White, A. W., Gallagher, S. J., Donaldson, M., McNaughton, G. and Heard, C. M. 2008. Scope and limitations of the co-drug approach to topical drug delivery. Current Pharmaceutical Design 14(8), pp. 794-802.
- White, A. W., Westwell, A. and Brahemi, G. 2008. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Reviews in Molecular Medicine 10(e8), pp. 1-14. (10.1017/S1462399408000641)
2004
- White, A. W. et al. 2004. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Biorganic and Medicinal Chemistry Letters 14(10), pp. 2433-2437. (10.1016/j.bmcl.2004.03.017)
2002
- Perdomo-Lopez, I., Rodriguez-Perez, A. I., Yzquierdo-Peiro, J., White, A. W., Estrada, E. G., Villa, T. G. and Torres-Labandeira, J. J. 2002. Effect of cyclodextrins on the solubility and antimycotic activity of sertaconazole: Experimental and computational studies. Journal of Pharmaceutical Sciences 91(11), pp. 2408-2415. (10.1002/jps.10237)
2000
- White, A. W. et al. 2000. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 43(22), pp. 4084-4097. (10.1021/jm000950v)
Erthyglau
- Owen, L., White, A. W. and Laird, K. 2019. Characterisation and screening of antimicrobial essential oil components against clinically important antibiotic-resistant bacteria using thin layer chromatography-direct bioautography hyphenated with GC-MS, LC-MS and NMR. Phytochemical Analysis 30(2), pp. 121-131. (10.1002/pca.2797)
- Lau, W. M., Heard, C. M. and White, A. W. 2013. Design, synthesis and in vitro degradation of a novel co-drug for the treatment of psoriasis. Pharmaceutics 5(2), pp. 232-245. (10.3390/pharmaceutics5020232)
- White, A. W., Carpenter, N., Lottin, J. R. P., McClelland, R. and Nicholson, R. 2012. Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. European Journal of Medicinal Chemistry 56, pp. 246-253. (10.1016/j.ejmech.2012.08.022)
- Lau, W. M., Ng, K. W., White, A. W. and Heard, C. M. 2011. Therapeutic and cytotoxic effects of the novel antipsoriasis codrug, naproxyl-dithranol, on HaCaT cells. Molecular Pharmaceutics 8(6), pp. 2398-2407. (10.1021/mp200327k)
- Lau, W. M., White, A. W., Donaldson, M. and Heard, C. M. 2010. Histochemical visualisation of esterase activity in porcine ear skin. Journal of Pharmacy and Pharmacology 62(6), pp. 798-798. (10.1211/jpp.62.06.0016)
- Lau, W. M., White, A. W. and Heard, C. M. 2010. Topical delivery of a naproxen-dithranol co-drug: in vitro skin penetration, permeation, and staining. Pharmaceutical Research 27(12), pp. 2734-2742. (10.1007/s11095-010-0274-8)
- Lau, W. M., White, A. W., Gallagher, S. J., Donaldson, M., McNaughton, G. and Heard, C. M. 2008. Scope and limitations of the co-drug approach to topical drug delivery. Current Pharmaceutical Design 14(8), pp. 794-802.
- White, A. W., Westwell, A. and Brahemi, G. 2008. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Reviews in Molecular Medicine 10(e8), pp. 1-14. (10.1017/S1462399408000641)
- White, A. W. et al. 2004. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Biorganic and Medicinal Chemistry Letters 14(10), pp. 2433-2437. (10.1016/j.bmcl.2004.03.017)
- Perdomo-Lopez, I., Rodriguez-Perez, A. I., Yzquierdo-Peiro, J., White, A. W., Estrada, E. G., Villa, T. G. and Torres-Labandeira, J. J. 2002. Effect of cyclodextrins on the solubility and antimycotic activity of sertaconazole: Experimental and computational studies. Journal of Pharmaceutical Sciences 91(11), pp. 2408-2415. (10.1002/jps.10237)
- White, A. W. et al. 2000. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 43(22), pp. 4084-4097. (10.1021/jm000950v)
Ymchwil
Research interests
Major interests concern the design and synthesis of novel anti-cancer agents. This involves synthetic organic chemistry, molecular modelling, purification methods and spectroscopy, particularly high field NMR, and close collaboration with biochemists. Particularly of interest is the development of natural product lead compounds as clinically useful chemotherapeutic agents.
Anti-cancer drug design
Structure-based drug design against various targets of interest including the DNA damage response, the EGFR-IGFR1 signalling pathway and the cell cycle. Several novel lead compounds have been identified that are currently undergoing further development.
Novel treatments for psoriasis
We have successfully developed a novel co-drug for the treatment of psoriasis with improved therapeutic and topical delivery properties compared to current treatments for the disease.
Natural Products Research
We have been investigating natural products from Welsh marine organisms and have identified anti-cancer activity in extracts from Welsh sponges. Currently involved in isolation and characterisation of discrete biologically active molecules.
Addysgu
Convenor of undergraduate examinations
- PH1121 Molecule to patient
- PH1122 The role of the pharmacist in professional practice
- PH1123 Structure and function of cells and microbes
- PH1124 Human body systems
- PH1125 Chemical and biological properties of drug molecules
- PH2110 Clinical & professional pharmacy
- PH2112 Principles of drug design
- PH2113 Diseases and drugs I
- PH3101 Optimisation of drug design
- PH3110 Optimisation of pharmaceutical care
- PH3202 Research methodology
- PH4116 Pharmacy research or scholarship project
- PH4117 Pharmaceutical sciences, pharmacy practice and the population
- PH4118 Pharmaceutical sciences, pharmacy practice and the patient
Bywgraffiad
Career profile
Graduated from the University of Newcastle upon Tyne and awarded a PhD in anti-cancer drug design from the same University. Held a faculty research position at the Arizona State University Cancer Research Institute under Professor Bob Pettit studying the anti-cancer constituents of marine organisms. Returned to the UK as a research associate at the Northern Institute of Cancer Research (1998-2000) and joined the staff of the School of Pharmacy and Pharmaceutical Sciences in 2000.
Contact Details
+44 29208 76308
Adeilad Redwood , Ystafell 1.81, Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB
